Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Alnylam’s pipeline is built on small interfering RNA (siRNA), synthetic molecules that silence specific mRNAs. After nearly 15 years of investment in the field, Alnylam is now nearing the moment ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Alnylam Pharmaceuticals (ALNY), a commercial-stage company, focuses on developing novel therapeutics based on RNAi. The ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post to the agency’s website. Published first on ...

Is Alnylam Pharmaceuticals (ALNY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals is one of 1010 individual ...

Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%. The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months. The ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global ...